A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity-score weighted multicenter approach

MeSH terms

• Benzylamines
• Biosimilar Pharmaceuticals / administration & dosage
• Biosimilar Pharmaceuticals / pharmacology*
• Blood Cell Count
• Cyclams
• Filgrastim / administration & dosage
• Filgrastim / pharmacology*
• Hematopoietic Stem Cell Mobilization*
• Heterocyclic Compounds / administration & dosage
• Heterocyclic Compounds / pharmacology*
• Humans
• Lymphoma, Non-Hodgkin / blood
• Lymphoma, Non-Hodgkin / therapy*
• Multiple Myeloma / blood
• Multiple Myeloma / therapy*
• Propensity Score
• Retrospective Studies